Indian Vaccine Market Size, Share, Price Trends, Report and Forecast, 2025

NEW YORK - Nov. 24, 2020 - PRLog -- According to the latest report by IMARC Group, the Indian vaccine market size is projected to reach INR 252 Billion by 2025, expanding at a CAGR of 17.8% during the forecast period (2020-2025). Vaccines refer to biological preparations consisting of an agent that is similar to a disease-causing pathogen to offer immunization against specific diseases. They are administered orally, by aerosol or through injections as a preventive measure for a number of diseases such as polio, measles, influenza and rabies. India currently represents one of the leading manufacturers and suppliers of vaccines in the world. It solely accounts for around 60% of the total vaccines supplied to the UNICEF, since the cost of manufacturing and clinical trials in India is relatively lower than in developed countries. Moreover, technological advancements and improved cold chain storage facilities have led to increased vaccine production capacity in the country.

Indian Vaccine Market Trends:

One of the major drivers of the Indian vaccine market is the strong government support to the manufacturers. Steady government funding and successful initiatives have resulted in considerable market development over the years. Also, various government-funded campaigns have created widespread health awareness among the masses. For instance, the Universal Immunization Program (UIP) introduced by the Government with the aim to increase immunization coverage against vaccine preventable diseases in the country has significantly boosted the demand for vaccines. Besides this, the growing investments from private sector players to develop and distribute vaccines throughout the country, as well as in the international market, has strengthened the present vaccine manufacturing infrastructure. Apart from this, continuous research and development (R&D) activities have enabled manufacturers to introduce new and improved vaccines in the market. Some of the other factors positively influencing the market growth are increasing population, elevating incomes, improving cold chain logistics and active NGO participation.

Request to get sample report: https://www.imarcgroup.com/indian-vaccine-market/requests...

Market Summary:

The market has been analyzed on the basis of various monovalent and combined vaccines into Bacillus Calmette–Guérin (BCG), Haemophilus influenzae type b (Hib), Influenza, Varicella, Typhoid, Japanese Encephalitis, Measles, Tetanus Toxoid, Hepatitis A, Rubella, Diphtheria, Tetanus and Pertussis (DPT), Oral Polio Vaccine (OPV), Measles, Mumps and Rubella (MMR), Rotavirus, Hepatitis B, Pneumococcal, Meningococcal, Rabies, Human Papillomavirus (HPV), Hexavalent and Dengue.

The competitive landscape of the market has also been examined, with some of the key players being GlaxoSmithKline Plc, Sanofi-Aventis Groupe, Serum Institute of India, Panacea Biotec Limited., Pfizer Inc., Novartis International AG, VHB Life Sciences Limited, Cadila Healthcare Ltd. (Zydus Cadila) and Merck Sharp & Dohme Corporation (MSD).

Browse full report: https://www.imarcgroup.com/indian-vaccine-market

Contact Us

IMARC Group
Tel: +1-631-791-1145
Email: sales@imarcgroup.com
Website: https://www.imarcgroup.com
Follow us on twitter: @imarcglobal